Castle Biosciences (CSTL) vs TriSalus Life Sciences (TLSI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Castle Biosciences (CSTL) has outperformed TriSalus Life Sciences (TLSI) over the past year, gaining 42.9% versus a loss of 14.8%. Over five years, CSTL leads with a -47.0% price change compared with -58.3% for TLSI. Castle Biosciences is the larger company by market cap ($1.04 billion vs $247.2 million), about 4.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CSTL | TLSI |
|---|---|---|
| Share price | $34.18 | $4.02 |
| Market cap | $1.04B | $247.22M |
| 1-day change | +1.38% | -2.78% |
| YTD return | -13.34% | -40.83% |
| 1-year return | +42.90% | -14.85% |
| 5-year return | -46.98% | -58.28% |
| EPS (TTM) | $-0.64 | $-1.22 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $44.28 | $7.95 |
| 52-week low | $17.72 | $2.20 |
| Distance from 52-week high | -22.82% | -49.50% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +32.00% | +159.03% |
| Average volume | 402.90K | 275.38K |
| Shares outstanding | 30.55M | 61.57M |
| Employees | 1,002 | 102 |
| Sector | Health Care | Health Care |
| Industry | Medical Specialities | Medical Specialities |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Castle Biosciences is about 4.2 times larger than TriSalus Life Sciences by market value ($1.04B vs $247.22M).
- CSTL has outperformed TLSI by 57.7 percentage points over the past year.
About Castle Biosciences
CSTL stock →Castle Biosciences, Inc., a molecular diagnostics company, provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), atopic dermatitis (AD), and uveal melanoma. The company offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test that predicts the likelihood of a positive sentinel lymph node and the risk of metastasis for patients with invasive cutaneous melanoma; TissueCypher, a risk stratification spatialomics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, and low-grade dysplasia BE; AdvanceAD-Tx, a non-invasive GEP test which is designed to guide systemic treatment selection for patients aged 12 years and older with moderateto-severe AD; DecisionDx-SCC, a GEP test for cutaneous squamous cell carcinoma; and MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions.
Health Care · Medical Specialities · 1,002 employees
About TriSalus Life Sciences
TLSI stock →TriSalus Life Sciences, Inc. engages in the research, development, and commercialization of drug delivery technology platform and immuno-oncology therapeutics to improve outcomes for patients with difficult-to-treat liver and pancreatic cancers in the United States.
Health Care · Medical Specialities · 102 employees
CSTL vs TLSI FAQ
Which is bigger, Castle Biosciences or TriSalus Life Sciences?
Castle Biosciences (CSTL) is larger, with a market capitalization of $1.04B compared with $247.22M for TriSalus Life Sciences (TLSI).
Which stock has performed better over the past year, CSTL or TLSI?
CSTL returned +42.90% over the past 12 months, compared with -14.85% for TLSI (price return, excluding dividends). Past performance does not predict future results.
Are Castle Biosciences and TriSalus Life Sciences in the same industry?
Yes. Both are classified in the Medical Specialities industry within the Health Care sector.